Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12082578 | 0.86 | GRM5 (0.41) | MAOAMAOBHRH3GRM5DRD4 | |
| SCHEMBL12082592 | 0.84 | NAMPT (0.38) | MAOAMAOBHRH3GRM5DRD4 | |
| SCHEMBL31125639 | 0.82 | MAOA (0.35) | MAOAMAOBHRH3DRD4DRD2 | |
| SCHEMBL18726583 | 0.81 | MAOA (0.34) | MAOAMAOBHRH3DRD4DRD2 | |
| SCHEMBL20284220 | 0.81 | GRM5 (0.34) | GRM5DRD4FGFR1FGFR2FGFR3 | |
| SCHEMBL20793348 | 0.78 | HRH3 (0.33) | MAOAMAOBHRH3CYP1A2CYP2D6 | |
| SCHEMBL438780 | 0.78 | GRM5 (0.33) | GRM5FGFR1FGFR2FGFR3ACVR1 | |
| SCHEMBL2606745 | 0.78 | PIK3R1 (0.35) | HRH3GRM5FGFR1FGFR2FGFR3 | |
| SCHEMBL30703875 | 0.78 | HRH3 (0.35) | MAOAMAOBHRH3CYP1A2CYP2D6 | |
| SCHEMBL10325665 | 0.75 | GRM5 (0.44) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117561256-A | Crystal form of biphenyl derivative inhibitor and preparation method thereof | 上海翰森生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| WO-2023274280-A1 | CRYSTAL FORM OF BIPHENYL DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2023-01-05 | — | — | WO | claimed |
| CN-115536657-A | Salt of biphenyl derivative inhibitor, crystal form and preparation method thereof | 上海翰森生物医药科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-113072551-B | Nitrogen-containing biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117561256-A | Crystal form of biphenyl derivative inhibitor and preparation method thereof | 上海翰森生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-113348170-B | Biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-111925367-B | Fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230149409-A1 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | INCYTE CORPORATION | 2023-05-18 | — | — | US | disclosed |
| WO-2023274280-A1 | CRYSTAL FORM OF BIPHENYL DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-06-05 | — | — | US | disclosed |
| US-7326791-B2 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-02-05 | — | — | US | disclosed |
| US-7326791-B2 | Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-02-05 | — | — | US | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004056784-A1 | NOVEL CARBOXAMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132496-A1 | CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | MAOA 54/4885MAOB 43/4885HRH3 190/4885 |
| US-20230149409-A1 | TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORS | PDCD1LG2, CD274, PDCD1 | MAOA 4496/4885MAOB 4369/4885HRH3 3083/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | MAOA 198/4885MAOB 32/4885HRH3 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.